ALVO Alvotech Feb 2026

alvo

Alvotech is not a typical development-stage biotech: it is a vertically integrated biosimilar platform that already generates hundreds of millions of dollars in revenue from launched products like AVT02 (adalimumab) and AVT04 (ustekinumab), while also running a crowded late-stage pipeline. The stock sits in that awkward middle ground between “early growth” and “heavy balance sheet”, with over 1B$ of debt but also positive adjusted EBITDA and operating profit in the latest 9-month period.

CRMD Thinking After Hours

This after-hours note starts from a simple, honest message in the comments. A reader who first bought CRMD around 11 USD, then averaged down at 9 USD and again at 6.5 USD, with one clear idea: one day, selling “north of 15” if the CorMedix story plays out.

RNXT RenovoRx Inc

Quick take: RenovoRx brings fresh clinical data on its TAMP™ therapy platform to SIO 2026 (February 6). The event is not a registrational readout, but it is a real-world test of how much the market still cares about this targeted intra-arterial delivery story as the company starts to generate device revenues.

DFTX Definium Therapeutics Inc.

Definium Therapeutics (DFTX) is not a mature commercial pharma story; it is a clinical‑stage CNS and mental health company whose equity behaves like a classic high‑beta biotech: the tape is dominated by expectations around clinical data, regulatory interactions, and the company’s ability to fund its programs through to value‑defining milestones.

ONCY Oncolytics Biotech, Inc

On February 4, 2026, Oncolytics announced that the FDA granted Fast Track designation to pelareorep combined with bevacizumab and FOLFIRI for adults with KRAS-mutant, microsatellite-stable metastatic colorectal cancer (MSS mCRC) in the second-line setting, after progression on a first-line oxaliplatin-based regimen. The designation is based on clinical signals from the REO 022 study and prior pelareorep experience across GI tumors and breast cance

VSTM Verastem Inc

Verastem Oncology enters 2026 as a very different story compared with two years ago. The company now has a commercial product, Avmapki Fakzynja (avutometinib + defactinib), approved under the FDA’s accelerated approval pathway for adult patients with KRAS-mutant recurrent low-grade serous ovarian cancer (LGSOC) after at least one prior systemic therapy.

ADMA Adma Biologics Inc

Commercial IG platform with three FDA-approved products, a yield-enhanced manufacturing process, and a revenue ramp from <$200M to >$500M in a handful of years. Not a binary biotech story, but an execution and capacity game that the market is finally treating like a growth compounder.

CCL Carnival Corporation February 2026

A comprehensive February 2026 strategic analysis of Carnival Corporation after the Q4 2025 earnings, the Excellence-class LNG fleet expansion, and the accelerated rollout of Carnival AI Operations Platform. Updated with latest SEC filings, January 2026 bookings data, and 2026-2027 sustainability targets. Educational only.

ONDS Ondas Inc

In early January we started to follow Ondas Inc. (ONDS) more closely on Merlintrader, first with a long-form deep-dive on the transformation of the group into an autonomous defense “system-of-systems” platform, and then with a sequence of updates as new contracts and Investor Day details emerged. Those articles focused on the structural story, the DCMA “Blue UAS” listing for Optimus and the growing defense pipeline.

OMER Omeros Corporation

What happened in January: Omeros successfully transitioned from pre-commercial biotech to commercial-stage rare disease company with the FDA approval of YARTEMLEA on December 23, 2025 and first commercial sales announced January 27, 2026.

PDYN Palladyne AI Updated feb 08

Palladyne AI announced a new contract with a major U.S. defense prime to deliver a mission-critical propulsion subsystem for an existing U.S. missile system. Management expects the award to generate nearly $1M in revenue, all booked in 2026, with hardware deliveries completed by the end of Q3 2026 according to the BusinessWire press release.

CYN Cyngn Inc

Cyngn (ticker CYN) sits in a corner of the market that many traders only notice when the tape goes vertical: micro-cap industrial autonomy. This is not a classical biotech binary, not a cash-generating SaaS giant, and definitely not a clean “AI story” with nine-figure revenues. It is a company trying to turn a fairly sophisticated autonomy stack into a repeatable, contract-driven business in forklifts, tuggers and other industrial vehicles – while burning real money and living under the constant threat of dilution.

BBAI BigBear.ai Holdings Inc

BigBear.ai started as a data-fusion and analytics contractor, grew via acquisitions and went public through the GigCapital4 SPAC at the end of 2021. The company’s value proposition is to make sense of messy data streams and provide actionable recommendations for operators in defense, intelligence, border security, logistics and other complex environments. To do that, it combines traditional analytics, AI/ML models, simulation, and mission-planning tools into a single decision-intelligence laye

2026 The New Era – Watchlist Space-AI-Defense

2026 opens in a geopolitical environment that looks like a “Cold War 2.0” – but running at a much higher speed and across more domains than anything we have seen before. Classic threat pillars – nuclear deterrence, air and sea control, conventional superiority – are still there, but they have been reshaped by disruptive technologies that make them far more lethal and unpredictable.

BFRI Biofrontera Inc

Photodynamic-therapy specialist with a single commercial franchise (Ameluz + RhodoLED) in U.S. dermatology, entering a dense 2026 data and regulatory window while revenues scale from the low–mid $40M range and the balance sheet remains tight.

PHAR Pharming Group Adr-CRL

On February 1, 2026, Pharming announced that the U.S. FDA issued a Complete Response Letter (CRL) to its supplemental New Drug Application (sNDA) for Joenja (leniolisib) in children aged 4 to 11 years with activated phosphoinositide 3-kinase delta syndrome (APDS). The letter does not question the fundamental clinical benefit of leniolisib in APDS but raises two specific technical concerns

CRMD CorMedix Inc

CorMedix is no longer the pre-revenue story that dialysis investors watched from a distance. After the U.S. launch of DefenCath in 2024, the company has delivered its first profitable quarter, acquired the Melinta anti-infective portfolio, built a meaningful cash position and, as of February 2026, added a $75 million share repurchase program on top.

ARTV Artiva Biotherapeutics Inc

Artiva Biotherapeutics is a clinical-stage biotech company focused on off-the-shelf allogeneic NK cell therapies built on a standardized, donor-derived, manufacturing platform. The lead asset, AlloNK (AB-101), is being developed in combination with anti-CD20 therapy both in B-cell non-Hodgkin lymphoma (NHL) and in autoimmune d